Skip to content

Efficacy of acupuncture for accelerating the negative conversion of the elderly COVID-19 positive patients: study protocol for a prospective randomized controlled trial

Efficacy of acupuncture for accelerating the negative conversion of the elderly COVID-19 positive patients: study protocol for a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005887
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-04-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus (COVID-19)

Interventions

Control:placebo acupuncture plus usual care group
Acupuncture:Acupuncture at the bilateral Zusanli (ST36) plus usual care group

Sponsors

Shanghai Fourth People's Hospital, School of Medicine, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9) to determine the patients of asymptomatic infection (medical obseration period) and mild patients. 2. Within 5 days of the first positive nucleic acid test. 3. Aged 65 years and older. 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to acupuncture, including local skin damage, infection or inplanted electrophysiological devices. 2. Communication barriers, inability to cooperate with researchers, such as language comprehension barriers, mental illness, etc. 3. Uncontrolled hypertension, diabetes, coronary heart disease, cardiac insufficiency; severe liver and kidney dysfunction. 4. Patients with tumors or inflammatory bowel disease that can cause delayed wound healing. 5. Those who are not suitable for acupuncture, such as abnormal coagulation function or bleeding tendency. 6. Those who do not obey random grouping. 7. Other factors that may affect the results of the study or those who are not suitable to enter the trial according to the judgement of the investigator. 8. Those who have participated in other clinical trials within 3 months before being enrolled in the study.

Design outcomes

Primary

MeasureTime frame
the Negative Conversion time of Viral nucleic acid detection;Negative rate of viral nucleic acid detection within 10 days;

Secondary

MeasureTime frame
Duration of main symptoms (fever, cough, fatigue) and symptom score;Duration and symptom score of other symptoms (including expectoration, chest tightness, diarrhea, etc.);Total hospitalization days;

Countries

China

Contacts

Public ContactLize Xiong

Shanghai Fourth People's Hospital, School of Medicine, Tongji University

mzkxlz@126.com+86 13609283068

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026